Qiagen N.V. logo

Qiagen N.V.

QGEN

NYSEHealthcareMedical - Diagnostics & Research

Previous close

$44.07

−$0.83 · -1.85%

Aug 21, 4:02 PM ET

QGEN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

94

Deep Value

Momentum

56

Neutral

Sentiment

63

Bullish

Risk resilience

59

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
NL
CEO
Thierry Bernard
Listed since
Jun 28, 1996
Employees
5,500

Market position

Day range

Current $44.07

52-week range

Current $44.07

Open
$44.29
Previous close
$44.90
Volume
2.9M
1.08× average
Average volume
2.68M
Average daily volume
Market cap
9.09B USD
Beta
0.62
Market reference 1
50-day average
$40.6864
+8.32% above average
200-day average
$42.7616
+3.06% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
10.66B USD
P/E (TTM)
22.6×
P/B (TTM)
2.71×
P/S (TTM)
4.33×
EV / EBITDA
14.86×
Earnings yield
4.32%
Free cash flow yield
4.60%
Dividend yield
5.99%

Profitability & efficiency

Gross margin
61.82%
Operating margin
25.33%
Net margin
19.49%
Return on equity
11.25%
Return on assets
6.75%
Return on invested capital
7.80%

Financial health

Debt / equity
0.49×
Current ratio
3.9×

Earnings

EPS beat rate
73%
8 beats, 1 miss, 2 met estimates
Average EPS surprise
+3.50%
11 comparable reports
Latest EPS result
0.62
Estimate 0.6 · Beat by 3.68%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.680.610.540.46Q1 '25BeatQ2 '25BeatQ3 '25MetQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 0.61, estimate 0.6, surprise +1.67%, Beat. Q2 2025, reported May 7, 2025: actual 0.55, estimate 0.503, surprise +9.34%, Beat. Q3 2025, reported Aug 5, 2025: actual 0.6, estimate 0.6, surprise 0.00%, Met estimate. Q4 2025, reported Nov 4, 2025: actual 0.64, estimate 0.61, surprise +4.92%, Beat. Q1 2026, reported Feb 4, 2026: actual 0.62, estimate 0.61, surprise +1.64%, Beat. Q2 2026, reported May 6, 2026: actual 0.54, estimate 0.542, surprise -0.37%, Miss. Q3 2026, reported Aug 5, 2026: actual 0.62, estimate 0.598, surprise +3.68%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 0.63, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates562.04M523.78M485.51M447.25MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 521.2M USD, estimate 518.54M USD, surprise +0.51%, Beat. Q2 2025, reported May 7, 2025: actual 483.46M USD, estimate 468.87M USD, surprise +3.11%, Beat. Q3 2025, reported Aug 5, 2025: actual 533.54M USD, estimate 515.76M USD, surprise +3.45%, Beat. Q4 2025, reported Nov 4, 2025: actual 532.58M USD, estimate 525.91M USD, surprise +1.27%, Beat. Q1 2026, reported Feb 4, 2026: actual 540.42M USD, estimate 528.42M USD, surprise +2.27%, Beat. Q2 2026, reported May 6, 2026: actual 492.32M USD, estimate 496.15M USD, surprise -0.77%, Miss. Q3 2026, reported Aug 5, 2026: actual 535.04M USD, estimate 527.5M USD, surprise +1.43%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 535.87M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

30 ratings
Strong buy00%
Buy1343%
Hold1757%
Sell00%
Strong sell00%

QGEN news

QGEN peers

ETFs holding QGEN

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research QGEN

research.disclaimer